Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally Suppressed Subjects With Chronic Hepatitis B

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally Suppressed Subjects With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS 4774 (Primary)
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 19 May 2016 Results published in the Journal of Hepatology
    • 13 Nov 2015 Results from this trial will be presented at the Liver Meeting 2015, according to a GlobeImmune media release.
    • 27 May 2015 Primary endpoint (Mean change in log10 IU/mL serum hepatitis B surface antigen (HBsAg) from Baseline to Week 24) has not been met, according to a GlobeImmune media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top